On October 2, 2025, Merit Medical Systems, Inc. announced that its SCOUT® Radar Localization system has reached 750,000 patients treated worldwide, marking a major milestone in the adoption of the company’s wire‑free breast‑cancer localization technology.
SCOUT® uses a tiny reflector to provide ±1 mm accuracy for surgeons, enabling precise removal of abnormal breast tissue while minimizing trauma to healthy tissue. The system is already used in 50 countries, with more than 500 cases performed each day and 10,000 cases per month, and the company has added SCOUT MD, a next‑generation system that offers four reflector shapes for enhanced tumor margin mapping.
The 750,000‑patient milestone signals strong market acceptance and suggests continued revenue growth from SCOUT sales and related services. It also positions Merit as a leader in breast‑cancer care during Breast Cancer Awareness Month, reinforcing the company’s strategic focus on high‑impact, high‑margin medical devices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.